Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

134

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Regorafenib and tislelizumab

Tislelizumab: 200mg, iv, d1, Q3W; Regorafenib: 40-120mg, po, qd, d1-21, d22-d28 discontinuation Q4W

DRUG

Regorafenib

Regorafenib: 40-120mg, po, qd, d1-21, d22-d28 discontinuation Q4W

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER